Untreated or missed urinary tract infections can lead to bladder or kidney infections, causing patients further pain and illness and putting them at risk of developing urosepsis, which can lead to death in the worst cases.

As a leader in infectious disease testing and a top urinary tract infection testing lab, we know UTIs should be treated with urgency.

95% of our molecular UTI test results are delivered the same day we receive the sample.

When it comes to patient health and safety, the quality of diagnostic testing is not a compromise to make.

Acutis Reveal™ UTI is the first PCR-based urinary tract infection test approved by the Clinical Laboratory Evaluation Program (CLEP) – a third-party reviewer for the FDA and a division of the NYSDOH.

Quickly identify pathogens, determine whether the infection is fungal or bacterial, and receive enhanced treatment insights with our urinary tract infection test.

Our laboratory-developed UTI test, Acutis Reveal™ UTI, offers:

• Simultaneous detection and identification of >90% of the bacteria and fungal pathogens responsible for UTI

• 96-100% sensitivity and 100% specificity; including the detection of fastidious organisms

• Polymicrobial infection detection, without the use of the common, inaccurate pooling technique

Urinary tract infections are among the world's most common infections, but many of the medications used to treat urinary tract infections, especially recurring ones, have become less effective as antibiotic resistance increases.  

Acutis Reveal™ UTI is followed by information on antibiotic sensitivity – our enhanced antibiotic sensitivity testing (AST) process.

Our molecular UTI test and AST information provide actionable data that can assist in preventing misdiagnoses and subsequent inappropriate use of antibiotics while enabling clinicians to define the right course of treatment for an infection.